Granules India Ltd.

NSE: GRANULES | BSE: 532482 | ISIN: INE101D01020 | Industry: Pharmaceuticals
| Mid-range Performer
529.9500 -4.00 (-0.75%)
NSE Jun 06, 2025 15:31 PM
Volume: 485.8K
 

529.95
-0.75%
Motilal Oswal
24 May 2018 GRANs 4QFY18 sales rose significantly by ~39% YoY to INR5b (est. Gross margin shrank to 38.5% from 57% in 4QFY17 and 49.1% in 3QFY18, primarily due to higher RM prices, one-time write-off related to obsolete inventory, and product mix change. EBITDA fell ~44% YoY to INR436m (est. of INR760m), with the margin down ~1,300bp YoY to 8.7% due to certain write-offs. Weak operating performance led to a decline in PAT by ~55% YoY to INR204m (est. For FY18, sales, EBITDA and PAT stood at INR16.9b (~18%), INR2.8b (-7%) and INR1.4b (-18%), respectively.
Motilal Oswal decreased Buy price target of Granules India Ltd. to 600.0 on 28 May, 2025.
More from Granules India Ltd.
Recommended